Most eczema treatments work the same basic way: they block the inflammatory signals that trigger flares. A new drug in testing takes the opposite route, boosting the body’s own calming immune cells instead, and early results suggest it could work just as well, if not better, especially for the treatment-resistant cases dermatologists see most often.
As reported by Dermatology Times, rezpegaldesleukin, made by Nektar Therapeutics, met its main goal in a mid-stage trial of adults with moderate to severe eczema, with meaningful improvement showing up in as little as two weeks.
A Different Kind of Eczema Drug
Most of today’s prescription eczema treatments, including biologics like Dupixent and Adbry, work by shutting down the specific proteins that spark inflammation. Rezpegaldesleukin skips that step entirely. It targets regulatory T cells, a type of immune cell whose job is to calm inflammation rather than trigger it, and gets the body to make more of them on its own.
What the Trial Found
At the highest dose tested, patients saw their eczema severity drop by about six in 10 points on a standard scale by week 16, and roughly four in 10 reached a threshold doctors consider a strong clinical response. On placebo, fewer than two in 10 hit that mark. Itch, often the most disruptive symptom for eczema patients, improved substantially too, and patients on the drug also reported real gains in sleep and quality of life.
What Dermatologists Are Saying
Washington dermatologist Jonathan I. Silverberg, MD, PhD, MPH, professor of dermatology at George Washington University School of Medicine and the study’s principal investigator, called the data a milestone for the field: “These results represent the first large, randomized, placebo-controlled trial to demonstrate that selectively expanding regulatory T cells can translate into clinically meaningful improvements across both physician-assessed and patient-reported outcomes in patients with atopic dermatitis.”
He added that the approach could open up new options for people who have not been helped by existing eczema treatments: “We have the opportunity with rezpegaldesleukin to alter the treatment paradigm and provide a novel alternative for the many patients with moderate to severe atopic dermatitis who are inadequately treated today.”
What This Means for You
Rezpegaldesleukin still has to clear larger, phase 3 testing before it could reach patients, so this is not a treatment to ask your dermatologist about just yet. Researchers are also exploring it for alopecia areata and type 1 diabetes. If those results hold up, it could eventually give people with treatment-resistant eczema a meaningfully different option, one that works with the immune system instead of against it.
